Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 8/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | EIF4EBP1 | Q13541 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4880247 | 0.87 | PTGER1 (0.79) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL14028965 | 0.84 | PTGER1 (0.60) | PTGER1CYP2C9EIF4EBP1NPC1HPGD | |
| SCHEMBL14029163 | 0.84 | PTGER1 (0.60) | PTGER1CYP2C9EIF4EBP1NPC1HPGD | |
| SCHEMBL30850464 | 0.78 | EIF4EBP1 (0.48) | PTGER1CYP2C9EIF4EBP1 | |
| SCHEMBL5096044 | 0.77 | PTGER1 (0.62) | PTGER1CYP2C9EIF4EBP1CYP3A4 | |
| SCHEMBL5096241 | 0.77 | PTGER1 (0.54) | PTGER1CYP2C9EIF4EBP1CYP3A4 | |
| SCHEMBL21158562 | 0.76 | L3MBTL1 (0.54) | CYP2C9NPC1CYP1A2HPGDCYP2C19 | |
| SCHEMBL5096086 | 0.76 | PTGER1 (0.72) | PTGER1CYP2C9EIF4EBP1CYP3A4 | |
| SCHEMBL5099258 | 0.75 | PTGER1 (0.77) | PTGER1CYP2C9CYP3A4 | |
| SCHEMBL14038705 | 0.75 | NPC1 (0.45) | PTGER1CYP2C9NPC1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | PTGER1, PTGER2, PTGDR | PTGER1 1/4885CYP2C9 820/4885EIF4EBP1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.